Company: DVAX
Filing Date: 2025-05-27
Form Type: DFAN14A
Source: 0001193125-25-125960
Chunk: 2

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-27
Form: DFAN14A
Chunk 2
---
 settlement discussions. Contrary to what                                                                                                                                        
 ISS wrote, the Company never made an offer that included re-balancing its classes. Also, our final proposal included a two-year standstill, another item that ISS                                                                           
 omits. Specifically, our final proposal was that Dynavax appoint Mr. Erkman and Mr. Santel to the Board, two incumbent directors step down, the share repurchase program be increased, and Deep Track would agree to a standstill until the 
 nomination period for the 2027 annual meeting.                                                                                                                                                                                              |

Shareholders should see through ISS’s surface-level analysis and consider the substantive issues at stake. Dynavax continues to underperform while the Board ignores its failed strategy. Our nominees possess exceptional relevant experience that could immediately improve the Board’s ability to assess the best path forward to maximize value. We urge shareholders to vote FOR our four highly qualified nominees.” EVERY VOTE MATTERS Your vote is important, no matter how many shares of Common Stock you own.

1

If you have any questions, require assistance in voting your proxy card, or need
additional copies of Deep Track’s proxy materials, please visit or contact our proxy solicitor, Innisfree M&A Incorporated (“Innisfree”), using the contact information provided here:

Innisfree M&A Incorporated

501 Madison Avenue, 20 Floor

New York, New York 10022

Stockholders call toll-free (877) 687-1865

About Deep Track Capital

Deep Track Capital is a
Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. We develop long term partnerships with management teams of leading innovative public and pre-IPO biotechnology
companies. In addition to capital, we seek to invest our time and expertise, while leveraging our network for the benefit of our partners. We aim to lead transactions while building large syndicates, and also to invest in rounds led by other
qualified investors.

Investor Contact

Innisfree
M&A Incorporated

Scott Winter / Gabrielle Wolf

+1 212-750-5833

Media Contact

Longacre Square Partners

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

The information herein contains “forward-looking statements.” Specific forward-looking statements can be identified by the fact that they do not
relate strictly to historical or current facts and include, without limitation, words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,”
“projects,” “potential,”